China's Leading CRO, Wuxi PharmaTech, Sees Relatively Smooth Sailing Ahead Following Tempest-marked Odyssey Of Global Crisis
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As the globe's pharmaceutical giants moved more research operations to lower cost China, the country's leading contract research organization, Wuxi PharmaTech, posted a strong rebound in 2009 earnings after recording a massive loss the previous year
You may also be interested in...
Japanese Nuclear Crisis Triggers Panic Buying Of Food And Drugs In China, Along With Selling Of Chinese Life Science Stocks
BEIJING - Virtual aftershocks from the 9.0 magnitude earthquake that rocked Japan, followed by a tsunami and a nuclear power plant crisis, are still reverberating across China
Japanese Nuclear Crisis Triggers Panic Buying Of Food And Drugs In China, Along With Selling Of Chinese Life Science Stocks
BEIJING - Virtual aftershocks from the 9.0 magnitude earthquake that rocked Japan, followed by a tsunami and a nuclear power plant crisis, are still reverberating across China
China's Leading Medical Equipment Maker Succeeds - Where Others Stumble - In Merging With U.S. Competitor
BEIJING - China's leading developer of medical devices, Mindray Medical International, is emerging as the golden success story in terms of a Chinese enterprise taking over an American competitor in the life sciences arena, with a 15.8 percent jump in net revenues for 2009 to $634.2 million